Calyxt Receives EU Patent on Use of CRISPR/Cas9 for Genome Editing in Plants

Minneapolis-St. Paul, Minn., December 17, 2018 – Calyxt, Inc. (NASDAQ: CLXT), a consumer-centric, food- and agriculture-focused company, today announced the issuance of European patent No. 3008186, which claims methods to create gene-edited plants by the transient delivery of sequence-specific nucleases, including CRISPR/Cas9. This patent, granted by the European Patent Office, is owned by Cellectis and … Continue reading Calyxt Receives EU Patent on Use of CRISPR/Cas9 for Genome Editing in Plants